Comparative Pharmacology
Head-to-head clinical analysis: DECADRON LA versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON LA versus STERANE.
DECADRON-LA vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory and immunosuppressive effects; suppresses migration of polymorphonuclear leukocytes, reverses increased capillary permeability, and reduces cytokine production.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
Dexamethasone acetate (DECADRON-LA) 8-16 mg intramuscularly every 1-3 weeks; adjust based on response and tolerance.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours for dexamethasone, but due to the acetate ester in Decadron-LA, absorption is prolonged, leading to an extended duration of action. The apparent half-life after intramuscular administration is about 3-4 days (72-96 hours) due to slow release from the injection site.
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Renal (<5% unchanged), hepatic metabolism with inactive metabolites excreted renally and fecally; urine and bile are minor routes. Exact % not specified for Decadron-LA (dexamethasone acetate), but dexamethasone is predominantly metabolized and metabolites are excreted renally (~80% of dose) and fecally (~20%).
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category C
Category C
Corticosteroid
Corticosteroid